p53 oncoprotein expression in cutaneous lymphoproliferations

Beylot‐Barry, M.

doi:10.1001/archderm.131.9.1019

Cited by 13 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15][16][17] In addition to palmar limitation, 10 there have been a few reports of palmoplantar DP without any further skin involvement. 18 DP limited to plantar sites, as in our patient, seems to be very rare.…”

Section: Discussionsupporting

confidence: 50%

Localized pemphigoid on the soles of both feet

Forschner

Fierlbeck

2005

Int J Dermatology

View full text Add to dashboard Cite

An 80-year-old woman was referred to our hospital with a spontaneously appearing bullous dermatosis limited to the soles of both feet, causing an intense pruritus. She also suffered from Parkinson's disease and depression, and had been treated with levodopa, benserazide, and mirtazapine for several years. On clinical examination, we found several tense and hemorrhagic bullae, with a diameter of up to 3 cm, at both plantar sites and multiple, confluent, dyshidrotic vesicles ( Figs 1 and 2). The rest of the skin, including the mucous membranes and palms, was normal. The first clinical diagnosis was podopompholyx, but histopathologic findings and direct immunofluorescence revealed a diagnosis of bullous pemphigoid, showing subepidermal blisters (Fig. 3) and linear deposits of C3 and immunoglobulin G (IgG). Indirect immunofluorescence was positive, the IgG autoantibodies bound to the epidermal site of salt-split skin, and circulating antibodies against bullous pemphigoid antigens 1 and 2 were found. Because of this typical clinical picture, a diagnosis of dyshidrotic pemphigoid, a localized form of bullous pemphigoid, was made. Under systemic treatment with prednisolone, 40 mg/day, the skin healed completely within 2 weeks. Descriptions of dyshidrotic pemphigoid limited to the soles of both feet are very rare, and the clinical findings might easily lead to a misdiagnosis of podopompholyx.

show abstract

Section: Discussionsupporting

confidence: 50%

Localized pemphigoid on the soles of both feet

Forschner

Fierlbeck

2005

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Groenbaeck et al (19), having applied PCR, investigated mis-sense and loss-of-function mutations in the p53 gene also in a small group of diffuse large B-cell lymphomas of the skin (REAL classification) and cutaneous MALT-type lymphomas and found no clear-cut correlation with expression of p53, which was present in 2 ⁄ 6 cases of the former type. Beylot-Barry et al (21), having applied the same antibody to p53 as in the present study, have found positive expression of p53 in five of six primary cutaneous high-grade B-cell lymphomas, which is in agreement with our own results. Interestingly, the PCMZL investigated in our study expressed no p53 (Table S2) which, in addition to phospho-Rb, might discern this subtype from the other types of PCBCL.…”

Section: Discussionsupporting

confidence: 93%

Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas

Kaune

Neumann

Hallermann

et al. 2011

Experimental Dermatology

View full text Add to dashboard Cite

The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene on chromosome 9p21 encodes p16 (INK4A), the inhibitor of the CDK4/retinoblastoma (Rb) cell proliferation pathway, as well as p14 (ARF), which controls p53-dependent pathways. Inactivation of p16 has previously been associated with the prognostically unfavourable primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT). In this work, we analysed 22 tumors [nine primary cutaneous follicle centre lymphomas (PCFCL), seven primary cutaneous marginal zone lymphomas (PCMZL) and six PCLBCL, LT] not only for alterations of the p16 gene but also for p14, p53 and Rb by fluorescence in situ hybridization (FISH) and immunohistochemistry. In most PCLBCL, LT (4/6) alterations of CDKN2A (two biallelic deletions, one monoallelic deletion and one trisomy 9) and in addition the highest frequency of deletions of p53 (3/6) and Rb (3/6) were detected. p16 was not expressed but very high levels of phosphorylated Rb, indicating a functional effect of genomic CDKN2A alterations on the protein level in PCLBCL, LT. Regarding the p14/p53 axis, PCLBCL, LT showed a variable expression. Neither PCFCL nor PCMZL showed alterations of CDKN2A and also deletions of p53 or Rb were extremely rare in these subtypes. Exclusively in PCMZL, p53 protein was consistently lacking. In conclusion, only PCLBCL, LT is characterized by a high frequency of aberrations of the CDKN2A network components in both important tumor suppressor pathways regulated by the CDKN2A gene. Moreover, PCLBCL, LT appears to be distinguishable from PCMZL not only by its level of p53 expression but also by its stage of Rb phosphorylation. The latter may also apply to a subgroup of PCFCL.

show abstract

“…other forms of malignancy, it is a relatively uncommon occurrence in CTCL. 30 Immunoreactivity with p53 has been observed more frequently in cutaneous lymphomas Acknowledgments of high grade malignancy and in patients with concurrent Ms Mary Helen Johnson and Ms Dorothea Dudek provided HIV infection. 31 On the other hand, Bcl-2 protein expreseditorial assistance in the preparation of the manuscript.…”

Section: Gr Analysismentioning

confidence: 99%